SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: AIKIDO PHARMA INC. (Note: Request metadata listed "Dominari Holdings Inc.", but the filing text identifies the registrant as AIKIDO PHARMA INC.)
Filing Date: March 5, 2021
Reporting Period: Current report for events occurring on or before March 5, 2021.
Business Context: The Company is a biopharmaceutical entity incorporated in Delaware, with common stock (Symbol: AIKI) traded on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding an upcoming investor presentation and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material changes to financial position or operations are reported in this document. The filing serves solely to announce a scheduled corporate event.
Guidance, Outlook, and Management Commentary
- Upcoming Event: The Company scheduled a presentation at the H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021.
- Investor Presentation: An investor presentation dated March 2021 is included as Exhibit 99.1.
- Legal Status of Information: The information furnished, including the exhibit, is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the investor presentation (Exhibit 99.1) for specific business updates, as the 8-K text itself contains no operational details.
- Confirm the date and format of the H.C. Wainwright & Co. Global Life Sciences Conference presentation (March 9, 2021, virtual).
- Note that the registrant name in the filing (AIKIDO PHARMA INC.) differs from the name in the request metadata (Dominari Holdings Inc.).